Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 15/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7209571 | 0.84 | HTT (0.41) | ELANEMEN1KMT2A | |
| SCHEMBL4409465 | 0.83 | CMA1 (0.49) | CMA1ELANEMEN1KMT2ACTRC | |
| SCHEMBL4405352 | 0.83 | MEN1 (0.40) | CMA1ELANEMEN1KMT2ABACE1 | |
| SCHEMBL4412440 | 0.81 | CMA1 (0.46) | CMA1ELANEKMT2ACTRC | |
| Trifluoroacetic Acid SCHEMBL1718165 | 0.80 | XIAP (0.47) | CMA1ELANE | |
| SCHEMBL7068303 | 0.77 | NPC1 (0.47) | MEN1KMT2A | |
| SCHEMBL13409468 | 0.75 | PREP (0.59) | ELANE | |
| SCHEMBL4406392 | 0.73 | CMA1 (0.43) | CMA1ELANEMEN1KMT2ABACE1 | |
| SCHEMBL13258959 | 0.73 | CMA1 (0.51) | CMA1ELANECTRC | |
| SCHEMBL2162326 | 0.73 | CMA1 (0.61) | CMA1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | CMA1 889/4885ELANE 1996/4885MEN1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.